Autopsy Findings in Lichen Myxedematosus

McCUISTION, C. H.

doi:10.1001/archderm.1956.01550090033007

Cited by 63 publications

(17 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…PUVA, Grenz ray, and electron beam therapy have also been used with mixed results [19]. Variable results have been obtained with systemic steroids [20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32] and daily cyclophosphamide [33, 34]. Pulse cyclophosphamide was effective in 1 patient [35].…”

Section: Discussionmentioning

confidence: 99%

Scleromyxedema: A Case Report and Review of the Literature

Allam

Ghozzi

2013

Case Rep Dermatol

View full text Add to dashboard Cite

Scleromyxedema (SM) is a sclerotic variant of lichen or papular mucinosis in which lichenoid papules and scleroderma-like features are both present. It is a rare deposition disorder characterized by generalized papular and sclerodermoid eruptions, mucin deposition, increased fibroblast proliferation, fibrosis, and monoclonal gammopathy (also known as paraproteinemia) mainly of the immunoglobulin G-lambda type in the absence of thyroid disease. It usually affects middle-aged adults and shows no gender or racial predilection. In addition to the skin findings and paraproteinemia, patients with SM have variable multisystem affections that mimic systemic sclerosis; the systems which are commonly involved include the gastrointestinal tract, musculoskeletal, pulmonary, cardiovascular, renal, and central nervous systems, leading to significant morbidity and mortality. Prominent symptoms include dysphagia, proximal muscle weakness, and dyspnea on exertion; less common but important findings include central nervous system involvement in the form of encephalopathy, convulsions, coma, and psychosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Scleromyxedema: A Case Report and Review of the Literature

Allam

Ghozzi

2013

Case Rep Dermatol

View full text Add to dashboard Cite

show abstract

“…Reported treatments include dermabrasion, 13 psoralen-UV-A, 14 systemic retinoids, 15,16 and corticosteroids. 7,17,18 Other reports of successful treatment include granulocyte colonystimulating factor, 19 plasmapheresis, 20 external beam irradiation, 21 intravenous immunoglobulin, 22 interferon alfa2a, 23 and extracorporal photopheresis. 24 Multiple chemotherapeutic agents have been used, including melphalan, 5,25,26 cyclosporine, 27 cladribine, 28 cyclophosphamide, 29,30 methotrexate, 31,32 and chlorambucil.…”

Section: Commentmentioning

confidence: 99%

Thalidomide as a Potential Treatment for Scleromyxedema

Caradonna¹

2004

Arch Dermatol

View full text Add to dashboard Cite

with a 1-year history of skin thickening. The process began on her hands and progressed to involve her arms, face, neck, shoulders, chest, and proximal extremities. Her only systemic complaints were limited mobility of her joints, particularly her hands and wrists. Physical examination findings revealed leonine facies. The skin of the neck, shoulders, and chest exhibited 1-to 2-mm coalescent linear papules. The skin of the hands, forearms, upper arms, and trunk was sclerotic. Skin biopsy results showed marked dermal thickening, displacement of collagen bundles by mucin, and numerous spindled fibroblasts, consistent with scleromyxedema. The results of laboratory tests, including a complete blood cell count, chemistry tests, liver function tests, an antinuclear antibody panel, an extractable nuclear antigen panel, and thyroid function tests, were normal. Immunoglobulins were obtained, and the following levels were revealed: IgM, 92 mg/dL (reference range, 25-210 mg/ dL); IgA, 152 mg/dL (reference range, 40-390 mg/dL); and IgG, 1490 mg/dL (reference range, 525-1650 mg/ dL), with a light chain monoclonal gammopathy. Hematologic evaluations, including serum and urine protein electrophoresis, immunoelectrophoresis, a bone marrow examination, and radiography of the head and chest, produced no evidence of multiple myeloma.Because of significant restriction of joint mobility, the patient underwent treatment with cytotoxic agents. She was initially treated with melphalan, 16 mg/d orally (PO), plus prednisone, 100 mg/d PO, for 4 days at a time in 1-month intervals for 4 cycles from

show abstract

“…but no thyroid or other endocrine abnormalities have been demonstrated. Monoclonal paraprotcinaemia of the IgG type is commonly associated with SM [1], Since the first report of a possible case of multiple myeloma asso ciated with SM [4], the etiologic role of a plasma cell dyscrasia has been suspected but not confirmed.…”

Section: Introductionmentioning

confidence: 99%

Normalization of Skin Appearance in a Patient with Scleromyxoedema after Intensive Chemotherapy for Hodgkin’s Disease

Alberts¹,

Schulz

Falkson³

et al. 1989

Dermatology

View full text Add to dashboard Cite

A patient with scleromyxoedema was treated for 6 years with cytostatic drugs. During this time the skin lesions followed a fluctuating but progressive course. After 6 years she developed Hodgkin’s lymphoma of the mixed cellularity type. Intensive cytostatic treatment given for Hodkin’s disease resulted in virtually complete disappearance of the scleromyxoedema lesions. The development of Hodgkin’s disease is considered fortuitous and not due to the previous cytostatic drugs.

show abstract

Autopsy Findings in Lichen Myxedematosus

Cited by 63 publications

References 2 publications

Scleromyxedema: A Case Report and Review of the Literature

Scleromyxedema: A Case Report and Review of the Literature

Thalidomide as a Potential Treatment for Scleromyxedema

Normalization of Skin Appearance in a Patient with Scleromyxoedema after Intensive Chemotherapy for Hodgkin’s Disease

Contact Info

Product

Resources

About